An antibody-drug conjugate directed against lymphocyte antigen 6 complex, locus E (LY6E) provides robust tumor killing in a wide range of solid tumor malignancies

Clinical Cancer Research

Volumn 21, Issue 14, 2015, Pages 3252-3262

  Asundi, Jyoti ^a   Crocker, Lisa ^a   Tremayne, Jarrod ^a   Chang, Peter ^b   Sakanaka, Chie ^c   Tanguay, Josh ^a   Spencer, Susan ^a   Chalasani, Sreedevi ^a   Luis, Elizabeth ^a   Gascoigne, Karen ^a   Desai, Rupal ^a   Raja, Rajiv ^a   Friedman, Brad A ^a   Haverty, Peter M ^a   Polakis, Paul ^a   Firestein, Ron ^a  

^a GENENTECH INC   (United States)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

^c PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; GLYCOSYLPHOSPHATIDYLINOSITOL; LYMPHOCYTE ANTIGEN 6 COMPLEX LOCUS E; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LY6E MONOMETHYLAURISTATIN E; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LY6E PROTEIN, HUMAN; MEMBRANE ANTIGEN; SMALL INTERFERING RNA; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; FEMALE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LUNG CANCER; LY6E GENE; LYSOSOME; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SOLID TUMOR; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; DRUG SCREENING; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOLOGY; NEOPLASM; POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942932701     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0156     Document Type: Article

References (28)

1. Burris HA Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 2011; 11: 807-19.
2. Foyil KV, Bartlett NL. Brentuximab vedotin for the treatment of CD30 +lymphomas. Immunotherapy 2011; 3: 475-85.
3. Schmeisser H, Mejido J, Balinsky CA, Morrow AN, Clark CR, Zhao T, et al. Identification of alpha interferon-induced genes associated with antiviral activity in Daudi cells and characterization of IFIT3 as a novel antiviral gene. J Virol 2010; 84: 10671-80.
4. Rubinfeld B, Upadhyay A, Clark SL, Fong SE, Smith V, Koeppen H, et al. Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nature Biotech 2006; 24: 205-9.
5. Bresson-Mazet C, Gandrillon O, Gonin-Giraud S. Stem cell antigen 2: a new gene involved in the self-renewal of erythroid progenitors. Cell Prolif 2008; 41: 726-38.
6. Asundi J, Lacap JA, Clark S, Nannini M, Roth L, Polakis P. MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma. Mol Cancer Ther 2014; 13: 1599-610.
7. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad 1992; 89: 4285-9.
8. Chen Y, Chalouni C, Tan C, Clark R, Venook R, Ohri R, et al. The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma. J Biol Chem 2012; 287: 24082-91.
9. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotech 2003; 21: 778-84.
10. Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, et al. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clin Cancer Res 2011; 17: 965-75.
11. Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, et al. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res 2012; 72: 2129-39.
12. Greenman CD, Bignell G, Butler A, Edkins S, Hinton J, Beare D, et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 2010; 11: 164-75.
13. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified geneinsmall-celllung cancer. Nature Genetics 2012; 44: 1111-6.
14. Tibshirani R, Wang P. Spatial smoothing and hot spot detection for CGH data using the fused lasso. Biostatistics 2008; 9: 18-29.
15. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
16. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-52.
17. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102: 1458-65.
18. Kumari S, Mg S, Mayor S. Endocytosis unplugged: multiple ways to enter the cell. Cell Res 2010; 20: 256-75.
19. Sangiorgio V, Pitto M, Palestini P, Masserini M. GPI-anchored proteins and lipid rafts. Ital J Biochem 2004; 53: 98-111.
20. Smart EJ, Anderson RG. Alterations in membrane cholesterol that affect structure and function of caveolae. Methods Enzymol 2002; 353: 131-9.
21. Subtil A, Hemar A, Dautry-Varsat A. Rapid endocytosis of interleukin 2 receptors when clathrin-coated pit endocytosis is inhibited. J Cell Sci 1994; 107: 3461-8.
22. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 2012; 18: 5160-2.
23. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Onc 2012; 9: 338-50.
24. Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 2007; 67: 4924-32.
25. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2010; 64: 15-29.
26. Senter PD Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009; 14: 235-44.
27. Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, et al. An anti-mesothelin-monomethyl auristatin E conjugate with potent antitumor activity in ovarian, pancreatic and mesothelioma models. Mol Cancer Ther 2014; 13: 2630-40.
28. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibodydrug conjugate. Clin Cancer Res 2010; 16: 888-97.